Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TL-925
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Telios Announces Successful Phase 2 Results for TL-925, a Treatment for Dry Eye Disease
Details : TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor, it is being investigated for the treament of individuals with moderate to severe dry eye disease (DED).
Product Name : TL-925
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2024
Lead Product(s) : TL-925
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable